NRx Pharmaceuticals to Announce Third Quarter Financials
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a dedicated clinical-stage biopharmaceutical firm, is set to unveil its financial results for the third quarter of 2025 on November 17, 2025, prior to the market's opening. This important news will be disseminated through a press release accessible on the company's official website.
Conference Call for Shareholders and Stakeholders
In conjunction with the release of its third quarter results, NRx Pharmaceuticals will conduct a conference call at 8:30 AM ET on the same day. This event aims to share crucial corporate updates, financial results, and operational plans moving forward. Investors and interested parties are encouraged to participate to gain insights directly from the company's leadership.
How to Join the Call
For those who wish to join the call, a live webcast will be hosted on the company's website. Additionally, participants can opt for dial-in access via telephone. Domestic attendees can call 1-800-717-1738, whereas international participants can reach the session by dialing +1-646-307-1865. This dual-access method ensures that all interested parties can engage with the company's key announcements and updates.
About NRx Pharmaceuticals
NRx Pharmaceuticals is heavily involved in developing groundbreaking therapies utilizing its innovative NMDA receptor platform, focused on addressing central nervous system disorders. Their current portfolio includes NRX-100, a preservative-free intravenous ketamine designed for suicidal ideation treatment, and NRX-101, an oral formulation combining D-cycloserine and lurasidone. Both products are aimed at serving patients suffering from chronic pain, PTSD, and severe depression.
Regulatory Milestones and Achievements
The company has made notable strides in receiving Fast Track Designation for NRX-100 to manage suicidal ideation in depression cases, especially within bipolar depression. Simultaneously, NRX-101 has been awarded Breakthrough Therapy Designation for similar indications. These designations highlight the products' potential and the pressing need for innovative solutions in mental health care.
New Drug Application Updates
NRx Pharmaceuticals is in the process of advancing its drug applications further. Recently, it re-filed an Abbreviated New Drug Application (ANDA) and is also pursuing a New Drug Application for NRX-100. This involves applying for the Commissioner's National Priority Voucher Program, emphasizing the urgency and importance of addressing suicidal ideation effectively.
Getting Further Information
For more details about NRx Pharmaceuticals and its endeavors, interested parties can reach out to the company representatives. Matthew Duffy, the Co-CEO, is available for inquiries related to corporate strategy and operations, and he can be contacted via email. Additionally, Brian Korb, the managing partner at Astr Partners, is also reachable for partnership-related questions. Their collaborative efforts reflect the firm’s commitment to advancing therapeutic solutions.
Contact Information
Matthew Duffy
Chief Business Officer
NRx Pharmaceuticals, Inc.
Email: mduffy@nrxpharma.com
Brian Korb
Managing Partner, Astr Partners
Phone: (917) 653-5122
Email: brian.korb@astrpartners.com
Frequently Asked Questions
What financial results will NRx Pharmaceuticals announce?
NRx Pharmaceuticals will report its third quarter financial results for 2025, including insights into revenue and operational performance.
How can I access the conference call?
Participants can join the call via a webcast on the company’s website or by telephone at the provided numbers.
What products is NRx Pharmaceuticals developing?
The company is focused on NRX-100 and NRX-101, targeting central nervous system disorders, particularly depression and PTSD.
What are the recent regulatory milestones?
NRX-100 has received Fast Track Designation, and NRX-101 has been awarded Breakthrough Therapy Designation, highlighting their potential impact in mental health treatment.
Who can I contact for more information?
Matthew Duffy and Brian Korb are the key contacts at NRx Pharmaceuticals for further inquiries regarding corporate strategy and partnerships.
